Literature DB >> 7134644

Rectal ammonia tolerance test in the evaluation of portal circulation in dogs with liver disease.

J Rothuizen, T S van den Ingh.   

Abstract

An ammonia tolerance test (ATT) is described in control dogs and in patients affected by liver disease with or without portosystemic collateral circulation. The administration of a 5 per cent ammonium chloride solution rectally proved to be preferable to oral administration. A statistically significant difference was shown between the results of the ATT in patients with and those without portal shunts, but not between control dogs and patients without portal collateral circulation. A simplified ATT is proposed in which venous ammonia determinations are made before and 20 and 40 minutes after rectal administration of 5 per cent ammonium chloride solution at a dose of 2 ml/kg bodyweight.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7134644

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  3 in total

Review 1.  Inherited liver shunts in dogs elucidate pathways regulating embryonic development and clinical disorders of the portal vein.

Authors:  Frank G van Steenbeek; Lindsay van den Bossche; Peter A J Leegwater; Jan Rothuizen
Journal:  Mamm Genome       Date:  2011-11-04       Impact factor: 2.957

2.  Aberrant gene expression in dogs with portosystemic shunts.

Authors:  Frank G van Steenbeek; Lindsay Van den Bossche; Guy C M Grinwis; Anne Kummeling; Ingrid H M van Gils; Marian J A Groot Koerkamp; Dik van Leenen; Frank C P Holstege; Louis C Penning; Jan Rothuizen; Peter A J Leegwater; Bart Spee
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

3.  Aberrant expression and distribution of enzymes of the urea cycle and other ammonia metabolizing pathways in dogs with congenital portosystemic shunts.

Authors:  Giora van Straten; Frank G van Steenbeek; Guy C M Grinwis; Robert P Favier; Anne Kummeling; Ingrid H van Gils; Hille Fieten; Marian J A Groot Koerkamp; Frank C P Holstege; Jan Rothuizen; Bart Spee
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.